Skip to main content
Terug
Watch Compare

Liminatus Pharma, Inc.

Datakwaliteit: 83%
Ook genoteerd als LIMNW Nasdaq
LIMN
Nasdaq Manufacturing Chemicals
€ 0,21
▲ € 0,02 (11,96%)
Marktkapitalisatie: 9,24 M
Prijs
€ 0,21
Marktkapitalisatie
9,24 M
Dagbereik
€ 0,18 — € 0,21
52-Weeksbereik
€ 0,16 — € 33,66
Volume
2.463.237
Openen € 0,18
50D / 200D Gem.
€ 0,45
54,32% below
50D / 200D Gem.
€ 2,58
92,01% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -9,98 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,42
Interest Coverage-13,75

Waardering

PE (TTM)
-0,91
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -10,21 M
ROE N/A ROA -627,86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -9,98 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,42
Interest Coverage -13,75 Asset Turnover N/A
Working Capital -1,66 M Tangible Book Value -1,65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,91 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -107,91%
Market Cap 9,24 M Enterprise Value 10,69 M
Per Share
EPS (Diluted TTM) -0,43 Revenue / Share N/A
FCF / Share -0,22 OCF / Share -0,22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 97,75%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -10,21 M
EPS (Diluted) -0,43
Gross Profit —
Operating Income -2,97 M
EBITDA —
R&D Expenses 2,69 M
SG&A Expenses —
D&A —
Interest Expense 215.903,0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 512.795,0
Total Liabilities 10,33 M
Shareholders' Equity -9,81 M
Total Debt 1,44 M
Cash & Equivalents —
Current Assets 500.574,0
Current Liabilities 10,30 M